Prognostic value of CD163(+) macrophages in solid tumor malignancies: a scoping review

Tools

Item Type:	Review
Title:	Prognostic value of CD163(+) macrophages in solid tumor malignancies: a scoping review
Creators Name:	Mathiesen, H., Juul-Madsen, K., Tramm, T., Vorup-Jensen, T., Møller, H.J., Etzerodt, A. and Andersen, M.N.
Abstract:	Tumor-associated macrophages (TAMs) play crucial roles in development and progression of malignant diseases. Notably, CD163(+) TAMs likely perform specific pro-tumorigenic functions, suggesting that this subset may serve as both prognostic biomarkers and targets for future anti-cancer therapy. We conducted a scoping review to map the current knowledge on the prognostic role of CD163(+) TAMs in the five most lethal cancers worldwide: Lung, colorectal, gastric, liver, and breast cancer. For all cancer types, most studies showed that high tumoral presence of CD163(+) cells was associated with poor patient outcome, and this association was more frequently observed when CD163(+) cells were measured at the tumor periphery compared to more central parts of the tumor. These results support that CD163(+) TAMs represent a biomarker of poor patient outcome across a variety of solid tumors, and highlight the relevance of further investigations of CD163(+) TAMs as targets of future immunotherapies.
Keywords:	Tumor-Associated Macrophage, CD163, Cancer, Solid Tumor Malignancy, Patient Prognosis, Targeted Immunotherapy
Source:	Immunology Letters
ISSN:	0165-2478
Publisher:	Elsevier
Page Range:	106970
Date:	6 January 2025
Official Publication:	https://doi.org/10.1016/j.imlet.2025.106970
PubMed:	View item in PubMed

Repository Staff Only: item control page